Ignite Creation Date:
2024-05-05 @ 11:49 AM
Last Modification Date:
2024-10-26 @ 9:14 AM
Study NCT ID:
NCT00149214
Status:
COMPLETED
Last Update Posted:
2012-03-21
First Post:
2005-09-02
Brief Title:
Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Phase 2 Trial of Doxorubicin Plus Pemetrexed Followed by Docetaxel Versus Doxorubicin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Treatment for Early Breast Cancer
Status:
COMPLETED
Status Verified Date:
2012-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
An open-label randomized Phase II study in order to explore two different sequential anthracycline-based neoadjuvant treatment regimens in female patients with primary operable breast cancer T2-T4N0-2M0
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-MC-S080 | OTHER | Eli Lilly and Company | None |